| 產(chǎn)品編號 | D51721 |
| 英文名稱 | K 03861 |
| 中文名稱 | |
| 別 名 | II型CDK2 抑制劑 |
| 性 狀 | Lyophilized |
| 保存條件 | Store in dry, dark place for one year. |
| 產(chǎn)品介紹 |
K 03861is a potent and selective Type II FLT3 inhibitor. K 03861 is able to override drug resistance that less potent "type I" inhibitors and "type II" first-generation FLT3 inhibitors cannot. Constitutively activated mutant FLT3 has emerged as a promising target for therapy for the subpopulation of acute myeloid leukemia (AML) patients who harbor it. The small molecule inhibitor, PKC412, targets mutant FLT3 and is currently in late-stage clinical trials. However, the identification of PKC412-resistant leukemic blast cells in the bone marrow of AML patients has propelled the development of novel and structurally distinct FLT3 inhibitors that have the potential to override drug resistance and more efficiently prevent disease progression or recurrence. |
